In This Article:
-
Full Year 2024 Sales: EUR932.8 million, a decrease of 3% compared to the previous year.
-
Gross Result: EUR401.4 million or 43% of sales, a decrease of 9% compared to last year.
-
R&D Expenses: 11.8% of sales.
-
G&A Expenses: 5.5% of sales.
-
Selling Expenses: 2.1% of sales.
-
Operating Result: EUR219.9 million or 23.6% of sales, a decrease of 16% compared to 2023.
-
Net Result: EUR171.4 million or EUR4.25 per share, a decrease of 18% compared to 2023.
-
Q4 2024 Sales: EUR197.4 million, a decrease of 21% compared to the same quarter of the previous year.
-
Q4 2024 Gross Result: EUR77.6 million or 39.3% of sales, a decrease of 31% compared to the same quarter of last year.
-
Q4 2024 Operating Result: EUR27.6 million or 14% of sales, a decrease of 55% compared to the same quarter of last year.
-
Q4 2024 Net Result: EUR18.3 million or EUR0.45 per share, a decrease of 63% compared to the fourth quarter of 2023.
-
Dividend Proposal: Total dividend of EUR3.7 gross per share for 2024.
-
2025 Q1 Sales Outlook: Expected to be in the range of EUR190 million to EUR200 million.
-
2025 H1 Sales Outlook: Expected to be around EUR400 million with a gross profit margin around 40% and an operating margin around 16%.
-
2025 CapEx Expectation: Around EUR50 million.
Release Date: February 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Melexis NV (XBRU:MELE) achieved a record number of product launches in 2024, setting a strong foundation for future sales growth.
-
The company continues to capture a strong level of design wins in both automotive and non-automotive applications, indicating robust innovation and market penetration.
-
Geographically, Melexis NV has shown strong design win performance in China, confirming strategic positioning in this key market.
-
Despite not meeting the original sales target, Melexis NV's 2024 sales were broadly stable and outperformed many peers.
-
The company is cautiously optimistic about improving customer demand around summer 2025, based on inventory corrections and market forecasts.
Negative Points
-
Melexis NV did not achieve its original sales target of EUR1 billion for 2024, which was a disappointment.
-
Sales for the full year 2024 decreased by 3% compared to the previous year, with a notable 21% decrease in Q4 sales year-over-year.
-
The operating result for 2024 decreased by 16% compared to 2023, reflecting challenges in maintaining profitability.
-
The net result for 2024 saw an 18% decrease compared to the previous year, impacting earnings per share.
-
The company is experiencing ongoing customer inventory corrections, which are expected to continue into the first half of 2025, affecting short-term sales outlook.